Limaryl M1 mg+500 mg

Limaryl M is a fixed-dose combination oral antidiabetic medicine indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

• Established/guideline-supported use: Patients with type 2 diabetes mellitus who are already being treated with a sulfonylurea and metformin separately, as a substitute for separate tablets to simplify the regimen.
• Established/guideline-supported use: Patients whose blood glucose is not adequately controlled on metformin alone (or a sulfonylurea alone) at the maximum tolerated dose, as a step-up combination therapy.
• Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.

Limaryl M is not a substitute for diet and exercise; it should be used together with an appropriate diabetes meal plan and physical activity as advised by a physician.

Glimepiride + Metformin tablets contain two active ingredients:

• Glimepiride – a second-generation sulfonylurea, typically available in strengths such as 1 mg, 2 mg, or 3 mg per tablet.
• Metformin hydrochloride – a biguanide, typically available in strengths such as 500 mg or 1000 mg per tablet.

Exact strength combinations vary by manufacturer and market; the prescribing physician selects the appropriate strength based on the patient's current glycemic control and prior monotherapy doses.

Limaryl M combines two complementary classes of oral antidiabetic agents in a single tablet. Glimepiride is a sulfonylurea that stimulates the pancreas to release more insulin, while metformin is a biguanide that reduces the liver's glucose production and improves the body's sensitivity to insulin.

By combining these two mechanisms, Limaryl M provides more effective blood glucose control than either agent alone in patients who need combination therapy, while allowing a lower dose of each individual component and improving treatment adherence through a single tablet.

Limaryl M belongs to the therapeutic class of oral antidiabetic combination agents, specifically combining a sulfonylurea (glimepiride) with a biguanide (metformin).

Glimepiride + Metformin works through two complementary mechanisms of action:

Glimepiride (sulfonylurea)

Glimepiride lowers blood glucose primarily by stimulating the release of insulin from functioning pancreatic beta cells. It binds to sulfonylurea receptors on beta cells, closing ATP-sensitive potassium channels, which leads to cell depolarization, calcium influx, and insulin secretion. It may also have modest extrapancreatic effects that increase peripheral tissue sensitivity to insulin.

Metformin (biguanide)

Metformin lowers blood glucose by decreasing hepatic glucose production (gluconeogenesis), decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not stimulate insulin secretion and therefore does not cause hypoglycemia when used alone.

Together, the two components of Glimepiride + Metformin act on different aspects of glucose regulation, providing complementary and additive glycemic control.

Limaryl M should be taken orally with food (usually with the first main meal of the day, or split with breakfast and dinner if taken twice daily) to minimize gastrointestinal upset and reduce the risk of hypoglycemia. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless directed otherwise. Doses should be taken at the same time(s) each day, and a missed dose should not be doubled up.

Limaryl M has clinically significant interactions with several medicines and substances:

• Iodinated contrast media: Concomitant use increases the risk of contrast-induced kidney injury and metformin-associated lactic acidosis; Limaryl M should be temporarily withheld before or at the time of a contrast imaging procedure and restarted only after renal function is confirmed normal.
• Alcohol: Acute or chronic alcohol use potentiates the effect of metformin on lactate metabolism, increasing the risk of lactic acidosis, and may also increase glimepiride-related hypoglycemia; alcohol should be avoided or used with caution.
• Other antidiabetic agents/insulin: Concomitant use with insulin or other glucose-lowering drugs increases the risk of additive hypoglycemia; blood glucose should be monitored closely and doses adjusted as needed.
• CYP2C9 inhibitors/inducers: Drugs that inhibit CYP2C9 (e.g., fluconazole) may increase glimepiride levels and hypoglycemia risk, while CYP2C9 inducers (e.g., rifampicin) may reduce glimepiride's effect and worsen glycemic control.
• Beta-blockers: May mask the warning signs and symptoms of hypoglycemia (such as tremor and palpitations), making hypoglycemia harder to recognize.
• NSAIDs, sulfonamides, and warfarin: May potentiate the hypoglycemic effect of glimepiride through protein-binding displacement or other mechanisms, increasing hypoglycemia risk.
• Cationic drugs eliminated by renal tubular secretion (e.g., cimetidine): May compete with metformin for renal elimination, increasing metformin levels.

Patients should inform their physician of all prescription, over-the-counter, and herbal medicines they are taking before starting Limaryl M.

Common and serious side effects of Limaryl M include:

• Hypoglycemia (low blood sugar) – due to the glimepiride component; symptoms include sweating, shakiness, hunger, confusion, and in severe cases, loss of consciousness. Risk is higher in the elderly, those with renal or hepatic impairment, or those who skip meals.
• Gastrointestinal upset – nausea, vomiting, diarrhea, abdominal discomfort, and a metallic taste, especially when starting metformin or increasing the dose; usually improves over time when taken with food.
• Vitamin B12 deficiency – with long-term metformin use, periodic monitoring may be advised, especially in patients with anemia or peripheral neuropathy.
• Weight gain – associated with the glimepiride component.
• Rare but serious: lactic acidosis – a rare but potentially life-threatening metabolic complication associated with metformin, more likely in patients with renal impairment, dehydration, sepsis, excessive alcohol intake, or hepatic impairment. Symptoms include unusual muscle pain, difficulty breathing, unusual tiredness, and abdominal discomfort; requires immediate medical attention.
• Other less common effects: headache, dizziness, skin rash, and mild elevations in liver enzymes.

Pregnancy: Limaryl M should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Insulin is generally the preferred agent for achieving glycemic control during pregnancy, as prolonged hyperglycemia is associated with an increased risk of congenital anomalies and other adverse outcomes, and oral antidiabetic agents are not generally recommended in pregnancy unless specifically advised by a specialist. A physician should be consulted before use in pregnancy or if pregnancy is planned or suspected.

Lactation: It is not well established whether the components of Limaryl M pass into human breast milk in clinically significant amounts. Because of the potential for hypoglycemia in a nursing infant, Limaryl M is generally not recommended during breastfeeding; a physician should be consulted to weigh the benefits of breastfeeding against alternative treatment options.

Limaryl M carries two serious safety concerns that require careful monitoring:

Lactic acidosis (metformin component)

Lactic acidosis is a rare but serious and potentially fatal metabolic complication that can occur due to metformin accumulation, particularly in the setting of renal impairment, dehydration, sepsis, excessive alcohol intake, hepatic impairment, or conditions causing tissue hypoxia (e.g., acute heart failure). Renal function should be assessed before starting Limaryl M and periodically thereafter. Limaryl M should be temporarily discontinued in situations of acute illness, dehydration, surgery, or before procedures using iodinated contrast media.

Hypoglycemia (glimepiride component)

Hypoglycemia risk is increased in elderly patients, those with renal or hepatic impairment, those who skip or delay meals, engage in unusual physical exertion, consume alcohol, or take other glucose-lowering medicines. Patients should be counseled on recognizing and managing hypoglycemia symptoms.

Other precautions

• Use with caution in patients with cardiovascular disease or conditions predisposing to reduced tissue oxygenation.
• Limaryl M should be temporarily withheld in patients undergoing surgery, significant dehydration, or serious infection until the clinical condition stabilizes.
• Regular monitoring of renal function, HbA1c, and, in long-term use, vitamin B12 levels is recommended.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency may rarely predispose to sulfonylurea-associated hemolytic anemia.

Overdose of Limaryl M can cause severe hypoglycemia (from the glimepiride component) and/or lactic acidosis (from the metformin component), both of which are medical emergencies. Symptoms of severe hypoglycemia may include confusion, seizures, loss of consciousness, while lactic acidosis may present with muscle pain, difficulty breathing, abdominal discomfort, and low blood pressure.

If an overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Do not attempt to manage a suspected overdose at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Elderly patients are at increased risk of both hypoglycemia (glimepiride) and lactic acidosis (metformin), often due to age-related decline in renal function. Limaryl M should be used with caution, starting at the lowest effective dose, with regular monitoring of renal function and blood glucose.

Renal impairment

Limaryl M is contraindicated in severe renal impairment due to the risk of metformin accumulation and lactic acidosis. Dose reduction and closer monitoring are needed in mild-to-moderate renal impairment, as advised by the physician.

Hepatic impairment

Limaryl M is contraindicated in severe hepatic impairment, as hepatic dysfunction can impair lactate clearance and increase lactic acidosis risk, and can also increase hypoglycemia risk from glimepiride.

Pediatric use

Safety and efficacy of Limaryl M in pediatric patients have not been established; it is not recommended for use in children.

Limaryl M is generally used as a long-term, ongoing treatment for type 2 diabetes mellitus, since diabetes is a chronic condition requiring continuous management. The duration of treatment is determined by the treating physician based on periodic assessment of blood glucose control, HbA1c levels, tolerability, and any emerging complications. Treatment should not be stopped abruptly without medical advice, as this can lead to loss of glycemic control.

Sulfonylurea + Biguanide (Oral Antidiabetic Combination)

Glimepiride + Metformin acts through two complementary mechanisms: glimepiride stimulates pancreatic beta cells to secrete more insulin, while metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. Together they lower blood glucose more effectively than either component used alone.

C

The safety and efficacy of Limaryl M have not been established in pediatric patients. Limaryl M is not recommended for use in children and adolescents under 18 years of age. Type 2 diabetes in children, when it occurs, should be managed under the direct supervision of a pediatric endocrinologist using treatments with established pediatric safety data.